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Suppression of Intestinal Polyposis
in ApcD716 Knockout Mice
by Inhibition of Cyclooxygenase 2 (COX-2)
Masanobu Oshima,* Joseph E. Dinchuk,† and endotoxins (Xie et al., 1992). Nonsteroidal anti-
inflammatory drugs (NSAIDs) inhibit the activity of bothStacia L. Kargman,‡ Hiroko Oshima,* Bruno Hancock,‡
Elizabeth Kwong,‡ James M. Trzaskos,† isozymes of COX, a property that accounts for their
Jilly F. Evans,‡ and Makoto M. Taketo*§ shared therapeutic and side effect profiles (Vane, 1971;
*Banyu Tsukuba Research Institute (Merck) Mitchell et al., 1994). Because conventional NSAIDs
Okubo, Tsukuba 300-33 such as indomethacin and sulindac inhibit both COX-1
Japan and COX-2, newer NSAIDs have been rigorously sought
†DuPont Merck Pharmaceutical Company that selectively inhibit COX-2 (Vane, 1994). Recently, we
Wilmington, Delaware 19880 and others constructed mouse mutants in which the
‡Merck Frosst Center for Therapeutic Research gene encoding COX-2 (Ptgs2) was inactivated by the
Pointe-Claire-Dorval knockout technology (Dinchuk et al., 1995; Morham et
Quebe´c, H9R 4P8 al., 1995). The homozygous mutant mice show ab-
Canada normalities in the kidney, heart and ovaries, causing
§Department of Biomedical Genetics reduced viability, renal dysplasia, cardiac fibrosis,
Faculty of Pharmaceutical Sciences and female infertility. Although many inflammatory re-
University of Tokyo sponses appeared unaffected, susceptibility to TNFa-
Hongo, Bunkyo 113 induced hepatocellular toxicity was markedly reduced
Japan (Dinchuk et al., 1995).
Accumulating evidence indicates that aspirin and
other NSAIDs may reduce theoccurrence orprogression
of colorectal cancer and polyps (Marnett, 1992; RaoSummary
et al., 1995). In a randomized, double-blind, placebo-
controlled study of 22 patients of familial adenomatousTwo cyclooxygenase isozymes catalyze conversion of
polyposis (FAP), patients treated with sulindac demon-arachidonic acid to prostaglandin H2: constitutive
strated a statistically significant decrease in the numberCOX-1 and inducible COX-2. To assess the role of
and size of polyps (Giardiello et al., 1993). To assessCOX-2 in colorectal tumorigenisis, we determined the
the role of COX-2 in colorectal polyposis and cancer,effects of COX-2 gene (Ptgs2) knockouts and a novel
and to evaluate the potential efficacy of COX-2 inhibitorsCOX-2 inhibitor on ApcD716 knockout mice, a model of
human familial adenomatous polyposis. A Ptgs2 null in treating patients, we determined the effects of COX-2
mutation reduced the number and size of the intestinal gene knockout and a COX-2-selective inhibitor on intes-
polyps dramatically. Furthermore, treating ApcD716 tinal polyposis using ApcD716 knockout mice, a mouse
mice with a novel COX-2 inhibitor reduced the polyp model of human FAP. Mutations in the human APC gene
number more significantly than with sulindac, which have been demonstrated to play a role in FAP as well as
inhibits both isoenzymes. These results provide direct sporadic cancers of the entire digestive tract (Boynton et
genetic evidence that COX-2 plays akey role in tumori- al., 1992; Horii et al., 1992; Powell et al., 1992). We re-
genesis and indicate that COX-2-selective inhibitors cently constructed a knockout mouse strain that devel-
can be a novel class of therapeutic agents for colo- ops numerous polyps in the intestinal tract as early as
rectal polyposis and cancer. three weeks of age due to a truncation mutation in the
Apc gene (ApcD716) (Oshima et al., 1995a). Due to the
loss of the full-length wild-type Apc allele (ApcFL) inIntroduction
the proliferative zone cells, i.e., loss of heterozygosity
(LOH) by the second hit, these microadenomas origi-Through the investigation of the mechanism of action
nated from single crypts by forming abnormal outpock-of aspirin and other anti-inflammatory drugs, cyclooxy-
ets into the inner (lacteal) side of the neighboring villi.genase (COX, PGHS, or PGH; prostaglandin-endoper-
This mutant mouse strain provided a useful model sys-oxide synthase, EC 1.14.99.1) has been established as
tem for investigation of various carcinogens, and forthe key enzyme responsible for prostanoid production
evaluation of anticancer and chemopreventive agents.(Vane, 1971, 1994). Conversion of arachidonic acid to
In fact, we demonstrated recently that heterocyclicprostaglandin G2 then to prostaglandin H2, is catalyzed
amines that are generated in overcooked meat stimulateby two isozymes, COX-1 and COX-2. COX-1 was initially
the growth of the intestinal polyps, whereas docosahex-characterized, purified, and cloned from sheep seminal
aenoic acid (DHA) reduces the number of polyps signifi-vesicles (Hemler and Lands, 1976; Miyamotoet al., 1976;
cantly when fed to the ApcD716mice (Oshima et al., 1995b,DeWitt and Smith, 1988) and is expressed constitutively
1996). Here we present the data that COX-2 plays a keyin many but not all mammalian tissues (O’Neill and Ford-
role in tumorigenesis and indicate that COX-2-selectiveHutchinson, 1993). In contrast, COX-2 is induced in in-
inhibitors can be a novel class of therapeutic drugs forflammatory cells such as monocytes and macrophages
polyposis and suitable chemopreventive agents for co-upon stimulation by cytokines (Maier et al., 1990), mito-
gens (Lee et al., 1992), serum (O’Banion et al., 1992), lorectal cancers.
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Figure 1. Immunoblot Analysis of COX-1 and
COX-2 Proteins in the Normal Mouse Small
Intestine and Colonic Epithelial Tissues and
in Polyps Isolated from ApcD716(1/2) Mice
(A–D) The proteins extracted from the normal
epithelium (lane 4) and polypsof various sizes
(lanes 5–9) were analyzed. Five, 10, and 20
ng of the purified sheep COX-1 (lanes 1–3)
and COX-2 (lanes 10–12) samples were
loaded as the positive controls. Samples from
the small intestine (A and B) and the colon (C
and D) were analyzed using polyclonal anti-
bodies against COX-1 (A and C) or COX-2 (B
and D). Note that the Mr for the sheep and
mouse enzymes are different as shown by
arrows on the margins (shp and mus, respec-
tively). For the normal epithelium and polyp
samples, 50 mg of microsomal protein were
loaded in each lane except for lane 5 (C and
D) where 30 mg of microsomal protein was
loaded.
Results control (statistical significance; P 5 0.0001, Figure 2A).
In the ApcD716(1/2) Ptgs2(2/2) mice, polyp numbers
were even lower; 93 6 98, i.e., z14% of the control (P <Cyclooxygenase-2 (COX-2) Is Induced at Very
Early Stages of Polyp Formation 0.0001, Figure 2A). Moreover, the size of the polyps
in the ApcD716(1/2) Ptgs2(2/2) mice were significantlyTo examine the expression of COX-1 and COX-2 in the
ApcD716 mice, we performed immunoblot analyses of smaller. As shown in Figure 2B, no polyps were found
larger than 2.0 mm in diameter, and most polyps werepolyp proteins using specific antibodies against COX-1
and COX-2, respectively. As shown in Figure 1A, the <1.0 mm. Interestingly, not a single colonic polyp was
found in the ApcD716(1/2) Ptgs2(2/2) mice, whereas thenormal intestinal epithelium, as well as the polyps of
various sizes isolated from the small intestine, ex- ApcD716(1/2) Ptgs2(1/2) and ApcD716(1/2) Ptgs2(1/1)
mice had 1.5 6 1.9 and 6.8 6 7.2 colonic polyps, respec-pressed COX-1 protein. Essentially the same result was
obtained with the normal colonic epithelium and the tively. These results indicate that expression of the
COX-2 gene increases the polyp number and size incolonic polyps (Figure 1C). These results are consistent
with earlier reports that COX-1 is a constitutive enzyme a gene dosage-dependent manner in the ApcD716(1/2)
mutant mice. This is the first direct genetic evidence(O’Neill and Ford-Hutchinson, 1993). In contrast, the nor-
mal epithelium of neither the small intestine nor the colon that COX-2 plays a key role in polyp formation.
contained any COX-2 protein detectable by this assay
(lane 4 in Figures 1B and 1D, respectively). However, Novel COX-2-Selective Inhibitor MF Tricyclic
Suppresses Polyp Formation in ApcD716 Micesmall intestinal polyps larger than 2 mm in diameter and
all colonic polyps (1–6 mm) contained significant levels in a Dosage-Dependent Manner
In order to determine whether we could mimic the Ptgs2of COX-2 protein (lanes 6–9 in Figure 1B and lanes 5–9 in
Figure 1D, respectively). Small intestinal polyps smaller mutation by administration of pharmaceutical agents,
we tested the effects of a novel COX-2-selective inhibi-than 2 mm did not show a detectable level of COX-2
(lane 5 in Figure 1B). These results indicate that COX-2 tor MF tricyclic and a nonselective COX inhibitor, sulin-
dac (Meade et al., 1993). As shown in Table 1, MF tricy-is not present in the normal epithelia, but induced in the
polyp tissues at a very early stage of polyp development. clic inhibited human COX-2 but not human COX-1 stably
expressed in CHO cells. In contrast, sulindac sulfide,
the active form of sulindac is a potent inhibitor of bothCOX-2 Gene (Ptgs2) Knockout Mutation
Introduced in ApcD716 Mice Reduces human COX-1 and COX-2. The controlApcD716(1/2) mice
fed with the drug-free diet for eight weeks had 424 6the Polyp Number in a Gene
Dosage-Dependent Manner 136 intestinal polyps (Figure 3). When fed at 14 and 3.5
mg/kg/day, MF tricyclic reduced the polyp numbers toTo determine the effect of the absence of COX-2 on
ApcD716 polyp formation, we introduced a knockout mu- 161 6 60 (P < 0.0001) and 210 6 110 (P 5 0.0037),
respectively. In contrast, the ApcD716(1/2) mice fed withtation (Dinchuk et al., 1995) of the COX-2 gene (Ptgs2)
into the ApcD716 knockout mice by two successive 12 mg/kg/day sulindac contained 312 6 117 polyps (P 5
0.0982; statistically not significant). Thus, MF tricycliccrosses and generated double-mutant mice that carried
ApcD716(1/2) Ptgs2(1/2) and ApcD716(1/2) Ptgs2(2/2) reduced the polyp numbers by 62% and 50% of the
control at 14 mg/kg and 3.5 mg/kg, respectively, com-mutations, respectively. The ApcD716(1/2) Ptgs2(1/1) lit-
ter mates were used as positive controls, which de- pared with only a 26% reduction of polyp number by
sulindac (Figure 3). Colonic polyps in the control wereveloped 652 6 198 (SD) polyps at the age of 10
weeks. When we examined the intestinal tracts of the 1.8 6 1.4 whereas those in ApcD716(1/2) mice fed 14
mg/kg and 3.5 mg/kg MF tricyclic were 0.3 6 0.6 andApcD716(1/2) Ptgs2(1/2) mice at the same age, polyp
numbers were reduced to 224 6 123, i.e., z34% of the 0.4 6 0.7, respectively.The numberof thecolonic polyps
Intestinal Tumor Suppression by COX-2 Inhibition
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Figure 3. Effect of a Novel COX-2 Inhibitor MF Tricyclic and Sulin-
dac on ApcD716(1/2) Mouse Intestinal Polyps
(A) Structure of MF tricyclic.
(B) Structure of sulindac.Figure 2. Effects of Ptgs2 Mutations on Intestinal Polyps in
(C) Number of polyps per mouse scored in ApcD716(1/2) mice fedApcD716(1/2) Ptgs2 (1/2) and ApcD716(1/2) Ptgs2(2/2) Mice, Com-
with the control diet, or diet with MF tricyclic or sulindac.pared with the ApcD716(1/2) Ptgs2(1/1) Controls
Circles indicate polyp numbers for individual females whereas(A) The mean numbers of polyps per mouse are shown with SD. (B)
squares indicate males. The number and vertical bar to the rightSize distribution of the intestinal polyps. Polyp sizes were classified
of each sample group indicate the mean polyp number and SD,according to their diameters in millimeters. Sample, n 5 8 random-
respectively. The drug doses have been calculated from the concen-ized mice for each group.
trations of the drugs in the diet and the actual diet intakes.
in the mice fed 12 mg/kg sulindac were 0.9 6 0.9. At day was 0.45 6 0.24 (SD) mg/ml. The mean plasma con-
these drug concentrations, neither MF tricyclic nor sulin- centration of the prodrug sulindac (fed 12 mg/kg/day)
dac significantly affected body weights, food intake, or was 0.54 6 0.52 mg/ml, whereas that of sulindac sulfide,
the general condition of the ApcD716(1/2) mice (data not the active form of sulindac, was 0.33 6 0.20 mg/ml and
shown). The plasma concentration of MF tricyclic in the that of the inactive metabolite sulindac sulfone was
mice fed 3.5 mg/kg/day was below the detection limit 7.9 6 4.8 mg/ml.
of 0.1 mg/ml, whereas that in the mice fed 14 mg/kg/
Inhibition of COX-2 Causes an Alteration
in Polyp Morphology
Table 1. COX Inhibition by MF Tricyclic and Sulindac Sulfide Suppression of the COX-2 activity, either by introduction
IC 50 (nM) COX-2/COX-1 of the knockout mutation or by COX-2-selective inhibitor
MF-tricyclic, had a profound effect on the polyp mor-Drug COX-1 COX-2 Ratio
phology as well. As shown in Figure 4A, well-developed
MF tricyclic .50,000 16.4 ,0.0003 polyps (i.e., larger than the nascent ones) in ApcD716(1/2)
Sulindac sulfide 47.9 1.2 0.03
Ptgs2(2/2) mouse intestines appeared recessed from the
The data are the mean of 2–18 individual determinations each per- surface of the surrounding villi under a dissection micro-
formed in duplicate in recombinant human COX-1 and COX-2 stably scope, whereas the polyps in ApcD716(1/2) Ptgs2(1/1)
expressed in CHO cells.
had similar heights to the villi (Figure 4B). Histologically,
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Figure 4. Polyp Morphology and Expression
of COX-2 in the ApcD716 Knockout Mouse In-
testine
(A and B) Dissecting micrographs of the in-
testinal mucosa containing well-developed
polyps in ApcD716(1/2) Ptgs2(2/2) (A), or
ApcD716(1/2) Ptgs2(1/1) (B) mice. Arrow-
heads indicate polyps viewed from the lumi-
nal side of the intestine. Scale bars, 0.5 mm.
(C and D) Histological sections of the intesti-
nal mucosa containing well-developed pol-
yps in ApcD716(1/2) Ptgs2(2/2) (C), or
ApcD716(1/2) Ptgs2(1/1) (D) mice. Arrows
indicate polyps in longitudinal sections. He-
matoxilin and eosin staining. Scale bars,
100 mm.
(E) Immunohistochemical staining of LacZ
protein expressed from the Ptgs2 promoter
in an intestinal polyp developed in the
ApcD716(1/2) Ptgs2lacZ(1/2) mouse. Arrows
indicate the major sites of expression.
(F and G) Histological sections adjoining the
one in (E) stained either with hematoxilin and
eosin (F) or non-immune rabbit IgG for the
primary antibody as a negative control (G).
(H) Immunohistochemical staining of LacZ
protein in an intestinal polyp developed in the
ApcD716(1/2) Ptgs2(1/1) mouse as a negative
control for (E).
Scale bars for (E)–(G), 100 mm.
this difference is clearly shown in Figures 4C and 4D. bacterial b-galactosidase gene (lacZ). In this construct,
the lacZ gene was placed under the control of the Ptgs2The Ptgs2(2/2) polyps were much flatter (shorter) than
those found in Ptgs2(1/1). Moreover, the Ptgs2(2/2) promoter and expressed as a fusion protein (Figure 5).
This knockout mutation was introduced into the ApcD716polyps were not covered with the normal intestinal epi-
thelium as in the Ptgs2(1/1) polyps. Although to a lesser knockout mice [ApcD716(1/2) Ptgs2lacZ(1/2)], and their
polyps were analyzed. As seen in Figure 5C, the levelextent, the same tendency was observed in polyps of
the ApcD716(1/2) Ptgs2(1/2) mice as well as of the of the COX-2 protein was reduced to a half level in the
(1/2) polyp tissue, and a strong band immunoreactiveApcD716(1/2) Ptgs2(1/1) mice treated with MF-tricyclic
(data not shown). with the LacZ antibodies was detected. When the polyp
sections were examined immunohistochemically using
specific antibodies against the bacterial enzyme, aIn the ApcD716 Polyps, COX-2 Is Expressed
Essentially in the Interstitial Cells Rather marked expression of LacZ protein was detected in the
polyps (Figure 4E). Interestingly, however, its expressionThan in the Intestinal Epithelium
To determine the site of COX-2 expression in the ApcD716 was found essentially in the interstitial cells with large,
ovoid and lightly stained nuclei, but not in the polyppolyps, we performed immunohistochemical analysis
using the specific antibodies against COX-2. However, epithelium itself (see an adjoining section stained by
H&E; Figure 4F). The specificity of this assay was verifiedour antibodies were not strong enough to detect any
signals in situ by immunohistochemistry (data not by two negative controls: an adjoining section stained
with a non-immune rabbit IgG sample (Figure 4G) andshown). To overcome this technical problem, we con-
structed another strain of Ptgs2 knockout mouse in a section of an ApcD716(1/2) polyp stained with the LacZ
antibodies, which did not detect any signals (Figure 4H).which one of the Ptgs2 alleles was interrupted by a
Intestinal Tumor Suppression by COX-2 Inhibition
807 11-20-96 14:32:02 060137$887
fact, accumulating evidence suggests that colorectal
carcinoma tissues from both human patients and rodent
models contain elevated levels of COX-2, the inducible
isozyme of COX (Eberhart et al., 1994; Kargman et al.,
1995; DuBois et al., 1996; Williams et al., 1996). Here,
we have demonstrated that COX-2 is induced in small
polyps in the ApcD716(1/2) intestines and colons (Figure
1). These results indicate that induction of COX-2 is a
very early event in the sequence of polyp formation to
colon carcinogenesis and suggest that COX-2 plays a
significant role in polyp development itself. Interestingly,
however, the COX-2 expression in the polyp tissues was
found essentially in the interstitial cells, rather than in
the polyp epithelium itself (Figure4E). Because themajor
prostanoid found in thecolorectal cancer tissues appear
to be prostaglandin E2 (PGE2; e.g., Rigas et al., 1993),
it is possible that the major end product of the PGH2
generated by COX-2 induced in the interstitial cells are
PGE2. It is also conceivable that the polyp epithelium
itself generates some prostacyclin (PGI2) because it has
been demonstrated in culture that rat intestinal epithe-
lium (RIE) cells stimulated by TPA or TGFa secrete PGI2
(DuBois et al., 1994). Tsujii and DuBois (1995) recently
expressed the COX-2 gene in RIE cells at high levels.
Such cells showed an increased tumorigenic potential
that was reversed by sulindac. Moreover, these cells
also have 3-fold increase in the duration of G1 that may
relate to the resistance of these cells to undergoFigure 5. Construction of the Ptgs2lacZ(1/2) Knockout Mouse Strain
by Homologous Recombination apoptosis (DuBois et al., 1996). It remains to be investi-
(A) Targeting strategy showing the structures of the wild-type Ptgs2 gated further how the expression of COX-2 in the polyp
gene (top), the targeting vector (middle) and the targeted allele (bot- interstitial cells influences these changes and how they
tom). Filled rectangles indicate exons whereas the open boxes show stimulate tumorigenesis.
the bacterial b-galactosidase gene–neomycin resistance gene cas-
In the experiments shown in Figures 2 and 3, thesette and the diphtheria toxin a subunit selection cassette, respec-
number of polyps in the control ApcD716 (1/2) mice aretively. The hatched box indicates the probe used for Southern hy-
larger than those we reported earlier (Oshima et al.,bridization analysis in (B). Only relevant XbaI sites are shown as X.
(B) Southern blot confirmation of the homologous recombinant ES 1995a). This is likely due to two reasons: improvement
cell clones. Genomic DNA from three recombinant ES cell clones in polyp counting (see Experimental Procedures) and
shown as (1/2) on the top of the gel are compared with two parental some background genes brought into ApcD716 mice from
ES cell samples (1/1). DNA preps were digested with XbaI and
the Ptgs2(1/2) mice. Two genes have been reported tohybridized using the probe shown in (A). Note that the 8.0 kb band
affect the polyp number in the ApcMin mice that containderived from the wild-type Ptgs2 alleles are reduced to a half density
a chemically induced truncation mutation in the Apcin the (1/2) clones and a new band of 5.0 kb appeared correspond-
ing to the knockout allele. gene at codon 850 (Moser et al., 1990; Su et al., 1992).
(C) Western immunoblot analysis of COX-2 (aCOX2, left) and LacZ When C57BL/6 ApcMin mice were crossed with 129/Sv
(aLacZ, right) proteins in the polyp tissues developed in ApcD716(1/2) DnmtS/1 heterozygous mice that contained the DNA
Ptgs2lacZ(1/2) mice (shown as 1/2) compared with polyps in the
methyltransferase gene null mutation, the polyp numbercontrol ApcD716 (1/2) Ptgs2(1/1) mice (shown as 1/1). Arrowheads
decreased to 41% and further to 2% when combinedindicate the bands for COX-2 (left) and LacZ (right). Note the COX-2
with a treatment with 5-azadeoxycytidine, an inhibitor ofband in the (1/2) lane is of a half density as in (1/1).
DNA methyltransferase (Laird et al., 1995). Homozygous
knockout mutants of the DNA methyltransferase gene
Discussion (Dnmts/s) are embryonic lethal (Li et al., 1992). On the
other hand, a major modifier gene affecting ApcMin-
Based on epidemiological data that showed a marked induced polyposis (Dietrich et al., 1993) has been pro-
reduction in mortality from colorectal carcinoma in indi- posed to encode secretory type II phospholipase A2
viduals taking NSAIDs, their efficacy in reducing the (gene symbol, Pla2s), and mouse strains that develop
number and size of the colonic polyps in human FAP many polyps such as C57BL/6 and 129/Sv have greatly
has been established recently in controlled trials (e.g., reduced levels of the enzyme (MacPhee et al., 1995). It
Giardiello et al., 1993). Likewise, NSAIDs have been is interesting that Pla2s encodes one of several enzymes
demonstrated to inhibit colorectal carcinogenesis in ani- that catalyze generation of arachidonic acid, the rate-
mal models as well (e.g., Reddy et al., 1993; Boolbol et limiting precursor of prostaglandins and leukotrienes.
al., 1996). Although the molecular mechanism in which Because expression of Pla2s (e.g., in the AKR strain)
NSAIDs reduce colorectal neoplasms remains unknown, reduces the polyp number rather than increases it, Pla2s
may affect polyposis in an indirect manner such asa likely possibility is through their inhibition of COX. In
Cell
808 11-20-96 14:32:02 060137$887
anti-rabbit IgG; Vector Res.) followed by incubation with avidin-through changing lipid homeostasis. Accordingly, the
biotin-peroxidase complex (Vector Res.), labeled with peroxidaseclinical relevance of these enzymes to intestinal polypo-
and colored with diaminobenzidine substrate.sis remains to be investigated.
Taken together, we have presented the first evidence
Determination of COX-1 and COX-2 Catalytic Activities
that COX-2 plays a key role in polyp formation and dem- Assays were performed induplicate with recombinant human COX-1
onstrated the basis for chemopreventive treatment of and COX-2, respectively, stably expressed in CHO cells as de-
polyposis and cancer by inhibitors of COX-2 such as scribed (Kargman et al., 1996).
MF tricyclic.
MF Tricyclic, Sulindac, and Sulindac Sulfide
These compounds were obtained from the COX-2 project team,Experimental Procedures
Merck Frosst.
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